- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
November 11, 2024Tommy Du Honored With 2024 Sheila Sonenshine Associate Pro Bono Award
-
December 3, 2024Can You Keep a Secret? Privacy Laws and Civil Litigation
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
November 6, 2024How Recent Patent Damages Precedent May Increase Reasonable Royalty Awards
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Winter 2017
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 17-1369 (D. Del.) | Oct. 2, 2017 | Hon. Gregory M. Sleet | Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,750,703
9,763,933
9,770,416
9,775,809
|
| Boehringer Ingelheim Pharms., Inc. v. Aurobindo Pharma USA Inc., 17-7887 (D.N.J.) | Oct. 4, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib dimaleate tablets) | 8,426,586 |
| Forest Labs. Holdings, Ltd. v. Strides Pharma Global PTE Ltd., 17-1394 (D. Del.) | Oct. 5, 2017 | Hon. Gregory M. Sleet | Savella® (milnacipran HCl tablets) |
6,602,911
7,888,342
7,994,220
|
| Boehringer Ingelheim Pharms., Inc. v. Hetero USA Inc., 17-7923 (D.N.J.) | Oct. 5, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib dimaleate tablets) | 8,426,586 |
| Purdue Pharma L.P. v. Collegium Pharm., Inc., 17-cv-11923 (D. Mass.) | Oct. 6, 2017 | Hon. F. Dennis Saylor, IV | Xtampza® ER (oxycodone extended-release capsules)XXOxyContin® (oxycodone HCl extended-release tablets) |
9,522,919
9,073,933
|
| Forest Labs. Holdings, Ltd. v. Strides Pharma Global PTE Ltd., 17-7996 (D.N.J.) | Oct. 6, 2017 | Hon. Brian R. Martinotti | Savella® (milnacipran HCl tablets) |
6,602,911
7,888,342
7,994,220
|
| Indivior Inc. v. Par Pharm., Inc., 17-7997 (D.N.J.) | Oct. 6, 2017 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,687,454 |
| Insys Therapeutics, Inc. v. Alkem Labs. Ltd., 17-1419 (D. Del.) | Oct. 10, 2017 | Hon. Leonard P. Stark | Syndros® (dronabinol oral solution) |
8,222,292
9,345,771
|
| Purdue Pharma L.P. v. Amneal Pharms., LLC, LLC 17-1421 (D. Del.) | Oct. 10, 2017 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) |
9,763,886
9,763,933
9,675,610
|
| Noven Pharms., Inc. v. Alvogen Pine Brook LLC, 17-1429 (D. Del.) | Oct. 11, 2017 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) |
9,730,900
9,724,310
|
| Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 17-2641 (D. Nev.) | Oct. 11, 2017 | Hon. Miranda M. Du | Vascepa® (icosapent ethyl capsules) |
8,293,728
8,318,715
8,357,677
8,367,652
8,377,920
8,415,335
8,426,399
8,440,650
8,518,929
8,524,698
8,546,372
8,617,594
|
| Hoffmann-La Roche Inc. v. Airis Pharma Private Ltd., 17-7912 (S.D.N.Y.) | Oct. 13, 2017 | Hon. Katherine B. Forrest | Valcyte® (valganciclovir HCl oral solution) |
9,642,911
8,889,109
|
| Boehringer Ingelheim Pharms., Inc. v. MSN Labs. Private Ltd., 17-8399 (D.N.J.) | Oct. 16, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib dimaleate tablets) | 8,426,586 |
| Sawai USA, Inc. v. Astellas Pharma Inc., IPR2018-00079 (PTAB) | Oct. 16, 2017 | N/A | Myrbetriq® (mirabegron extended-release tablets) | 6,346,532 |
| Takeda Pharms. U.S.A., Inc. v. Macleods Pharms. Ltd., 17-1469 (D. Del.) | Oct. 17, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Acrux DDS Pty Ltd. v. Sandoz, Inc., 17-3824 (S.D. Ind.) | Oct. 23, 2017 | Hon. Sarah Evans Barker | Axiron® (testosterone topical solution) |
8,435,944
8,993,520
9,180,194
|
| Bristol-Myers Squibb Co. v. Apotex Inc., 17-1493 (D. Del.) | Oct. 24, 2017 | Hon. Leonard P. Stark | Reyataz® (atazanavir sulfate capsules) | 6,087,383 |
| Sanofi-Aventis U.S. LLC v. Mylan N.V., 17-9105 (D.N.J.) | Oct. 24, 2017 | Hon. Stanley R. Chesler | Lantus® (insulin glargine injection)XXLantus® SoloSTAR® (insulin glargine injection) |
7,476,652
7,713,930
7,918,833
8,512,297
8,556,864
8,603,044
8,679,069
8,992,486
9,011,391
9,233,211
9,408,979
9,526,844
9,533,105
9,561,331
9,604,008
9,604,009
9,610,409
9,623,189
|
| Acrux DDS Pty Ltd. v. Sandoz, Inc., 17-2558 (D. Col.) | Oct. 25, 2017 | Hon. Nina Y. Wang | Axiron® (testosterone topical solution) |
8,435,944
8,993,520
9,180,194
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00119 (PTAB) | Oct. 25, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 7,964,580 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00120 (PTAB) | Oct. 25, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 7,964,580 |
| Sanofi-Aventis U.S. LLC v. Mylan N.V., 17-0181 (N.D.W.V.) | Oct. 26, 2017 | Hon. Irene M. Keeley | Lantus® (insulin glargine injection)XXLantus® SoloSTAR® (insulin glargine injection) |
7,476,652
7,713,930
7,918,833
8,512,297
8,556,864
8,603,044
8,679,069
8,992,486
9,011,391
9,233,211
9,408,979
9,526,844
9,533,105
9,561,331
9,604,008
9,604,009
9,610,409
9,623,189
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00121 (PTAB) | Oct. 26, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,334,270 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00122 (PTAB) | Oct. 26, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,334,270 |
| Pfizer Inc. v. Breckenridge Pharm., Inc., 17-1532 (D. Del.) | Oct. 30, 2017 | Hon. Leonard P. Stark | Xeljanz® (tofacitinib tablets) |
6,956,041
7,091,208
7,265,221
RE41,783
|
| Recro Gainesville LLC v. Actavis Labs. FL, Inc., 17-1535 (D. Del.) | Oct. 30, 2017 | Hon. Gregory M. Sleet | Zohydro® (hydrocodone bitartrate extended-release capsules) | 9,713,611 |
| Allergan Sales, LLC v. Sandoz, Inc., 17-10129 (D.N.J.) | Oct. 30, 2017 | Hon. William H. Walls | Combigan® (brimonidine tartrate / timolol maleate ophthalmic solution) | 9,770,453 |
| Forest Labs., LLC v. MSN Labs. Private Ltd., 17-10140 (D.N.J.) | Oct. 30, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00125 (PTAB) | Oct. 30, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,633,309 |
| Pfizer Inc. v. Umedica Labs. Pvt., Ltd., 17-1551 (D. Del.) | Oct. 31, 2017 | Hon. Richard G. Andrews | Viagra® (sildenafil citrate tablets) | 6,469,012 |
| iCeutica Pty Ltd v. Apotex, Inc., 17-1553 (D. Del.) | Oct. 31, 2017 | Vacant Judgeship (2017) | Zorvolex® (diclofenac capsules) |
8,679,544
8,999,387
9,017,721
9,173,854
9,180,095
9,180,096
9,186,328
|
| iCeutica Pty Ltd v. Apotex Inc., 17-1554 (D. Del.) | Oct. 31, 2017 | Vacant Judgeship (2017) | Vivlodex® (meloxicam capsules) |
9,526,734
9,649,318
|
| Forest Labs., LLC v. Prinston Pharm Inc., 17-10230 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Torrent Pharms. Ltd., 17-10273 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Westward Pharms. Int'l Ltd., 17-10321 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Zydus Pharms. (USA) Inc., 17-10330 (D.N.J.) | Oct. 31, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Hospira, Inc. v. Presenius Kabi USA, LLC, 17-7903 (N.D. Ill.) | Nov. 1, 2017 | Hon. Rebecca R. Pallmeyer | Precedex® (dexmedetomidine HCl injection) | 9,616,049 |
| ViiV Healthcare Co. v. Lupin Ltd., 17-1576 (D. Del.) | Nov. 2, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00126 (PTAB) | Nov. 2, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 9,284,342 |
| Pfizer Inc. v. Sun Pharm. Indus. Ltd., 17-1597 (D. Del.) | Nov. 7, 2017 | Hon. Leonard P. Stark | Xeljanz XR® (tofacitinib extended-release tablets) | RE41,783 |
| Mayne Pharma Int'l Pty Ltd. v. Actavis Elizabeth LLC, 17-1614 (D. Del.) | Nov. 9, 2017 | Vacant Judgeship (2017) | Doryx® MPC (doxycycline hyclate delayed-release tablets) |
6,958,161
9,295,652
9,446,057
9,511,031
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00123 (PTAB) | Nov. 9, 2017 | N/A | Harvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,735,372 |
| Apotex Inc. v. Abraxis Bioscience, LLC, IPR2018-00151 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 8,138,229 |
| Apotex Inc. v. Abraxis Bioscience, LLC, IPR2018-00152 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,820,788 |
| Apotex Inc. v. Abraxis Bioscience, LLC, IPR2018-00153 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,923,536 |
| Cipla Ltd. v. Abraxis Bioscience, LLC, IPR2018-00162 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,820,788 |
| Cipla Ltd. v. Abraxis Bioscience, LLC, IPR2018-00163 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 7,923,536 |
| Cipla Ltd. v. Abraxis Bioscience, LLC, IPR2018-00164 (PTAB) | Nov. 9, 2017 | N/A | Abraxane® (paclitaxel for injection) | 8,138,229 |
| AbbVie Inc. v. Cipla Ltd., 17-1631 (D. Del.) | Nov. 10, 2017 | Hon. Richard G. Andrews | Kaletra® (lopinavir / ritonavir tablets) |
7,148,359
7,364,752
8,025,899
8,268,349
8,309,613
8,377,952
8,399,015
8,470,347
8,691,878
|
| ViiV Healthcare Co. v. Apotex Inc., 17-1634 (D. Del.) | Nov. 10, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets)XXTivicay® (dolutegravir tablets) | 9,242,986 |
| Boehringer Ingelheim Pharms., Inc. v. Teva Pharms. USA, Inc., 17-11510 (D.N.J.) | Nov. 10, 2017 | Hon. Michael A. Shipp | Gilotrif® (afatinib tablets) |
RE43,431
8,426,586
|
| Mayne Pharma Int'l Pty Ltd. v. Lupin Ltd., 17-1637 (D. Del.) | Nov. 13, 2017 | Vacant Judgeship (2017) | Doryx® MPC (doxycycline hyclate delayed-release tablets) |
9,295,652
9,446,057
9,511,031
|
| AstraZeneca LP v. Prinston Pharm. Inc., 17-1639 (D. Del.) | Nov. 13, 2017 | Hon. Richard G. Andrews | Brilinta® (ticagrelor tablets) |
6,251,910
RE 46,276
7,250,419
7,265,124
|
| Par Pharm., Inc. v. Indivior Inc., 17-1280 (E.D. Va.) | Nov. 13, 2017 | Hon. Claude M. Hilton | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,687,454 |
| Delcor Asset Corp. v. Glenmark Pharms. Ltd., 17-1653 (D. Del.) | Nov. 15, 2017 | Hon. Richard G. Andrews | Evoclin® (clindamycin phosphate aerosol, foam) |
7,141,237
7,374,747
|
| Forest Labs., LLC v. Aurobindo Pharma USA, Inc., 17-11679 (D.N.J.) | Nov. 15, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Forest Labs., LLC v. Amneal Pharms. LLC, 17-11680 (D.N.J.) | Nov. 15, 2017 | Hon. Esther Salas | Fetzima® (levomilnacipran HCl extended-release capsules) |
8,481,598
8,865,937
RE43,879
|
| Eli Lilly and Co. v. Actavis LLC, 17-4299 (S.D. Ind.) | Nov. 16, 2017 | Hon. Tanya Walton Pratt | Alimta® (pemetrexed for injection) | 7,772,209 |
| ViiV Healthcare Co. v. Cipla Ltd., 17-1670 (D. Del.) | Nov. 17, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Mylan Pharms. Inc., 17-1671 (D. Del.) | Nov. 17, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Mylan Pharms. Inc., 17-0197 (N.D.W.V.) | Nov. 17, 2017 | Hon. Irene M. Keeley | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-1678 (D. Del.) | Nov. 20, 2017 | Vacant Judgeship (2017) | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-11873 (D.N.J.) | Nov. 20, 2017 | Hon. Brian R. Martinotti | Triumeq® (abacavir / dolutegravir / lamivudine tablets) | 9,242,986 |
| Takeda Pharms. U.S.A., Inc. v. Strides Pharma Global PTE Ltd., 17-1690 (D. Del.) | Nov. 21, 2017 | Hon. Richard G. Andrews | Colcrys® (colchicine tablets) |
7,906,519
7,935,731
8,093,298
7,964,648
8,093,297
7,619,004
7,601,758
7,820,681
7,915,269
7,964,647
7,981,938
8,093,296
8,097,655
8,415,395
8,415,396
8,440,721
8,440,722
|
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00168 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,549,938 |
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00169 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,566,289 |
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00170 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,566,290 |
| Flatwing Pharms., LLC v. Anacor Pharms., Inc., IPR2018-00171 (PTAB) | Nov. 21, 2017 | N/A | Kerydin® (tavaborole topical solution) | 9,572,823 |
| Shire Development LLC v. Teva Pharms. USA, Inc., 17-1696 (D. Del.) | Nov. 22, 2017 | Hon. Richard G. Andrews | Mydayis® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) |
6,913,768
8,846,100
9,173,857
|
| Onyx Therapeutics, Inc. v. Aurobindo Pharma USA, Inc., 17-1699 (D. Del.) | Nov. 22, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
7,737,112
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Mitsubishi Tanabe Pharma Corp. v. Aurobindo Pharma USA Inc., 17-12082 (D.N.J.) | Nov. 27, 2017 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) |
7,943,788
8,222,219
|
| Forest Labs., LLC v. Mylan Pharms. Inc., 17-1728 (D. Del.) | Nov. 30, 2017 | Hon. Richard G. Andrews | Linzess® (linaclotide capsules) | 9,708,371 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-1737 (D. Del.) | Dec. 1, 2017 | Vacant Judgeship (2017) | Tivicay® (dolutegravir tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Dr. Reddy's Labs., Inc., 17-12374 (D.N.J.) | Dec. 1, 2017 | Hon. Brian R. Martinotti | Tivicay® (dolutegravir tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Cipla Ltd., 17-1741 (D. Del.) | Dec. 4, 2017 | Vacant Judgeship (2017) | Tivicay® (dolutegravir tablets) | 9,242,986 |
| Mylan Technologies, Inc. v. Noven Pharms., Inc., IPR2018-00173 (PTAB) | Dec. 4, 2017 | N/A | Minivelle® (estradiol extended-release film) | 9,724,310 |
| Mylan Technologies, Inc. v. Noven Pharms., Inc., IPR2018-00174 (PTAB) | Dec. 4, 2017 | N/A | Minivelle® (estradiol extended-release film) | 9,730,900 |
| Mylan Pharms. Inc. v. Pozen Inc., IPR2018-00272 (PTAB) | Dec. 4, 2017 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,393,208 |
| Leo Pharma A/S v. Actavis Labs. UT, Inc., 17-1752 (D. Del.) | Dec. 6, 2017 | Hon. Joseph F. Bataillon | Picato® (ingenol mebutate gel) |
9,820,959
9,833,428
9,833,429
|
| Leo Pharma A/S v. Perrigo UK Finco Ltd., 17-1753 (D. Del.) | Dec. 6, 2017 | Hon. Joseph F. Bataillon | Picato® (ingenol mebutate gel) |
9,820,959
9,833,428
9,833,429
|
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00211 (PTAB) | Dec. 6, 2017 | N/A | Harvoni® (ledipasvir / sofosbuvir tablets) | 9,393,256 |
| Chiesi U.S.A., Inc. v. Teva Pharms. USA, Inc., 17-1772 (D. Del.) | Dec. 7, 2017 | Vacant Judgeship (2017) | Bethkis® (tobramycin injection solution) |
6,987,094
7,696,178
7,939,502
|
| Pfizer Inc. v. Aurobindo Pharma USA Inc., 17-1775 (D. Del.) | Dec. 8, 2017 | Hon. Leonard P. Stark | Tikosyn® (dofetilide capsules) | 6,124,363 |
| Noven Pharms., Inc. v. Mylan Technologies Inc., 17-1777 (D. Del.) | Dec. 8, 2017 | Hon. Leonard P. Stark | Minivelle® (estradiol extended-release film) |
9,730,900
9,724,310
|
| Valeant Pharms. Int'l, Inc. v. Actavis Labs. FL, Inc., 17-12857 (D.N.J.) | Dec. 8, 2017 | Hon. Stanley R. Chesler | Relistor® (methylnaltrexone bromide tablets) |
9,724,343
9,492,445
|
| Merck Sharp & Dohme Corp. v. Teva Pharms. USA, Inc., 17-6921 (D.N.J.) | Sept. 8, 2017 | Hon. Michael A. Shipp | Entereg® (alvimopan capsules) |
6,469,030
8,946,262
|
| ViiV Healthcare Co. v. Sandoz Inc., 17-1784 (D. Del.) | Dec. 11, 2017 | Vacant Judgeship (2017) | Tivicay® (dolutegravir tablets) | 9,242,986 |
| ViiV Healthcare Co. v. Sandoz Inc., 17-12912 (D. Del.) | Dec. 11, 2017 | Hon. Brian R. Martinotti | Tivicay® (dolutegravir tablets) | 9,242,986 |
| KVK-Tech, Inc. v. Shire PLC, IPR2018-00290 (PTAB) | Dec. 11, 2017 | N/A | Mydayis® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | 8,846,100 |
| KVK-Tech, Inc. v. Shire PLC, IPR2018-00293 (PTAB) | Dec. 11, 2017 | N/A | Mydayis® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) | 9,173,857 |
| Teva Pharms. Int'l GMBH v. Mylan Labs. Ltd., 17-1790 (D. Del.) | Dec. 12, 2017 | Hon. Gregory M. Sleet | Bendeka® (bendamustine HCl for injection) |
8,791,270
8,609,707
9,265,831
9,572,796
9,572,797
9,034,908
9,144,568
9,572,887
9,597,397
9,597,398
9,597,399
9,000,021
9,579,384
|
| Neos Therapeutics, Inc. v. Teva Pharms. USA, Inc., 17-1793 (D. Del.) | Dec. 13, 2017 | Hon. Gregory M. Sleet | Cotempla XR-ODT® (methylphenidate extended-release orally disintegrating tablets) |
8,840,924
9,072,680
9,089,496
|
| AstraZeneca Pharms. LP v. Fresenius Kabi USA, LLC, 17-1795 (D. Del.) | Dec. 14, 2017 | Vacant Judgeship (2017) | Faslodex® (fulvestrant for injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| AstraZeneca Pharms. LP v. Fresenius Kabi USA, LLC, 17-13075 (D.N.J.) | Dec. 14, 2017 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) |
6,774,122
7,456,160
8,329,680
8,466,139
|
| Amgen Inc. v. Watson Labs., Inc., 17-1807 (D. Del.) | Dec. 15, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Amgen Inc. v. Barr Labs., Inc., 17-1808 (D. Del.) | Dec. 15, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Amgen Inc. v. Teva Pharms. USA, Inc., 17-1809 (D. Del.) | Dec. 15, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Mitsubishi Tanabe Pharma Corp. v. Macleods Pharms., Ltd., 17-13130 (D.N.J.) | Dec. 15, 2017 | Hon. Peter G. Sheridan | Invokana® (canagliflozin tablets) |
7,943,582
8,513,202
|
| Bracco Diagnostics Inc. v. Maia Pharms., Inc., 17-13151 (D.N.J.) | Dec. 15, 2017 | Hon. Peter G. Sheridan | Kinevac® (sincalide for injection) | 6,803,046 |
| Arbor Pharms., LLC v. Taro Pharms. U.S.A., Inc., 17-9846 (S.D.N.Y.) | Dec. 15, 2017 | Hon. Sidney H. Stein | Sklice® (ivermectin lotion) |
8,791,153
8,927,595
|
| Gilead Sciences, Inc. v. Mylan Pharms. Inc., 17-0217 (N.D.W.V.) | Dec. 15, 2017 | Hon. Irene M. Keeley | Evotaz® (atazanavir / cobicistat tablets) | 8,148,374 |
| Onyx Therapeutics, Inc. v. Dr. Reddy's Labs., Inc., 17-1811 (D. Del.) | Dec. 18, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) |
7,417,042
7,232,818
7,491,704
8,129,346
8,207,125
8,207,126
8,207,127
8,207,297
|
| Eli Lilly and Co. v. Unichem Labs. Ltd., 17-13312 (D.N.J.) | Dec. 19, 2017 | Katharine S. Hayden | Cialis® (tadalafil tablets) | 6,943,166 |
| Millennium Pharms., Inc. v. Qilu Pharm. Co., Ltd., 17-1830 (D. Del.) | December 20, 2017 | Hon. Gregory M. Sleet | Velcade® (bortezomib for injection) |
6,713,446
6,958,319
|
| CyDex Pharms., Inc. v. Teva Pharms. USA, Inc., 17-1832 (D. Del.) | Dec. 20, 2017 | Hon. Leonard P. Stark | Evomela® (melphalan HCl for Injection) |
8,410,077
9,200,088
9,493,582
|
| Onyx Therapeutics, Inc. v. MSN Pharms., Inc., 17-1833 (D. Del.) | Dec. 20, 2017 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,737,112 |
| Shire Development LLC v. Rhodes Pharms. L.P., 17-1840 (D. Del.) | Dec. 21, 2017 | Hon. Richard G. Andrews | Adderall XR® (dextroamphetamine saccharate / amphetamine aspartate / dextroamphetamine sulfate / amphetamine sulfate extended-release capsules) |
RE41,148
RE42,096
|
| Impax Labs., Inc. v. Zydus Pharms. USA, Inc., 17-13476 (D.N.J.) | Dec. 21, 2017 | Hon. Stanley R. Chesler | Rytary® (levodopa / carbidopa capsules) | 9,089,608 |
| Amgen Inc. v. Torrent Pharms. Ltd., 17-1844 (D. Del.) | Dec. 22, 2017 | Hon. Gregory M. Sleet | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Initiative for Medicines, Access & Knowledge (I-MAK), Inc. v. Gilead Pharmasset LLC, IPR2018-00390 (PTAB) | Dec. 26, 2017 | N/A | Sovaldi® (sofosbuvir tablets)XXHarvoni® (ledipasvir / sofosbuvir tablets)XXEpclusa® (sofosbuvir / velpatasvir tablets)XXVosevi® (sofosbuvir / velpatasvir / voxilaprevir tablets) | 8,889,159 |
| Glaxo Group Ltd. v. Aurobindo Pharma USA, Inc., 17-1862 (D. Del.) | Dec. 27, 2017 | Vacant Judgeship (2017) | Lamictal XR® (lamotrigine extended-release tablets) |
8,637,512
9,144,547
|
| Osi Pharms., LLC v. Accord Healthcare Inc., USA, 17-1868 (D. Del.) | Dec. 28, 2017 | Hon. Gregory M. Sleet | Tarceva® (erlotinib HCl tablets) | 6,900,221 |
| Mallinckrodt IP Unlimited Co. v. Aurobindo Pharma USA, Inc., 17-1877 (D. Del.) | Dec. 29, 2017 | Hon. Leonard P. Stark | Ofirmev® (acetaminophen for injection) |
6,992,218
9,399,012
9,610,265
|
| Patheon Softgels Inc. v. Apotex Inc., 17-13819 (D.N.J.) | Dec. 29, 2017 | Hon. Michael A. Shipp | naproxen sodium OTC Capsules |
9,693,978
9,693,979
|
GENERICally Speaking Winter 2017
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
August 13, 2024
Allergan USA, Inc. v. MSN Labs. Private Ltd.
GENERICally Speaking Hatch Waxman Bulletin
Related News
October 14, 2022
September 9, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.